USD 2.16
(-8.86%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 43.92 Million USD | 105.19% |
2022 | 19.21 Million USD | 84.59% |
2021 | 10.41 Million USD | 32.65% |
2020 | 7.84 Million USD | 5550.69% |
2019 | -144 Thousand USD | -100.86% |
2018 | 16.68 Million USD | -44.94% |
2017 | 30.3 Million USD | 53.33% |
2016 | 19.76 Million USD | 87.12% |
2015 | 10.56 Million USD | 110.15% |
2014 | 5.02 Million USD | 185.41% |
2013 | 1.76 Million USD | -52.71% |
2012 | 3.72 Million USD | 18.69% |
2011 | 3.13 Million USD | 8.93% |
2010 | 2.88 Million USD | -15.13% |
2009 | 3.39 Million USD | -12.33% |
2008 | 3.87 Million USD | 21.19% |
2007 | 3.19 Million USD | -10.88% |
2006 | 3.58 Million USD | 2.01% |
2005 | 3.51 Million USD | 583.98% |
2004 | 513.77 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | 10.93 Million USD | -5.25% |
2024 Q2 | 12.16 Million USD | 21.47% |
2023 Q1 | 8.71 Million USD | 20.64% |
2023 Q4 | 11.54 Million USD | -8.04% |
2023 FY | 39.43 Million USD | 105.19% |
2023 Q2 | 9.99 Million USD | 14.63% |
2023 Q3 | 12.55 Million USD | 25.66% |
2022 Q2 | 2.92 Million USD | 3.02% |
2022 FY | 19.21 Million USD | 84.59% |
2022 Q3 | 6.22 Million USD | 112.46% |
2022 Q4 | 7.22 Million USD | 16.09% |
2022 Q1 | 2.84 Million USD | 7.89% |
2021 Q3 | 2.56 Million USD | -9.79% |
2021 Q4 | 2.63 Million USD | 2.85% |
2021 FY | 10.41 Million USD | 32.65% |
2021 Q1 | 2.37 Million USD | 41.45% |
2021 Q2 | 2.84 Million USD | 19.58% |
2020 Q2 | 2.34 Million USD | 0.0% |
2020 FY | 7.84 Million USD | 5550.69% |
2020 Q1 | 2.34 Million USD | 194.97% |
2020 Q4 | 1.67 Million USD | 0.0% |
2020 Q3 | 1.67 Million USD | -28.34% |
2019 Q4 | -2.46 Million USD | 0.0% |
2019 FY | -144 Thousand USD | -100.86% |
2019 Q1 | 2.48 Million USD | -20.18% |
2019 Q2 | 2.48 Million USD | 0.0% |
2019 Q3 | -2.46 Million USD | -199.4% |
2018 Q4 | 3.1 Million USD | 0.0% |
2018 FY | 16.68 Million USD | -44.94% |
2018 Q1 | 5.26 Million USD | -4.69% |
2018 Q2 | 5.26 Million USD | 0.0% |
2018 Q3 | 3.1 Million USD | -40.92% |
2017 Q3 | 5.52 Million USD | -42.66% |
2017 Q2 | 9.63 Million USD | 0.0% |
2017 Q4 | 5.52 Million USD | 0.0% |
2017 Q1 | 9.63 Million USD | 68.81% |
2017 FY | 30.3 Million USD | 53.33% |
2016 Q4 | 5.7 Million USD | 0.0% |
2016 Q1 | 4.22 Million USD | 48.08% |
2016 Q3 | 5.7 Million USD | 34.92% |
2016 Q2 | 4.22 Million USD | 0.0% |
2016 FY | 19.76 Million USD | 87.12% |
2015 Q1 | 2.51 Million USD | 75.05% |
2015 Q3 | 2.85 Million USD | 13.67% |
2015 Q4 | 2.85 Million USD | 0.0% |
2015 FY | 10.56 Million USD | 110.15% |
2015 Q2 | 2.51 Million USD | 0.0% |
2014 Q2 | 1.17 Million USD | 0.0% |
2014 FY | 5.02 Million USD | 185.41% |
2014 Q4 | 1.43 Million USD | 0.0% |
2014 Q3 | 1.43 Million USD | 22.23% |
2014 Q1 | 1.17 Million USD | 632.43% |
2013 Q2 | 1.1 Million USD | 0.0% |
2013 FY | 1.76 Million USD | -52.71% |
2013 Q1 | 1.1 Million USD | -2.8% |
2013 Q3 | -220.5 Thousand USD | -120.03% |
2013 Q4 | -220.5 Thousand USD | 0.0% |
2012 Q2 | 931.04 Thousand USD | 0.0% |
2012 Q1 | 931.04 Thousand USD | 18.69% |
2012 Q3 | 1.16 Million USD | 25.12% |
2012 Q4 | 1.13 Million USD | -2.77% |
2012 FY | 3.72 Million USD | 18.69% |
2011 Q1 | 784.45 Thousand USD | 8.93% |
2011 Q4 | 784.45 Thousand USD | 0.0% |
2011 FY | 3.13 Million USD | 8.93% |
2011 Q2 | 784.45 Thousand USD | 0.0% |
2011 Q3 | 784.45 Thousand USD | 0.0% |
2010 Q4 | 720.17 Thousand USD | 0.0% |
2010 Q2 | 720.17 Thousand USD | 0.0% |
2010 Q3 | 720.17 Thousand USD | 0.0% |
2010 Q1 | 720.17 Thousand USD | -15.13% |
2010 FY | 2.88 Million USD | -15.13% |
2009 Q1 | 848.54 Thousand USD | -12.33% |
2009 Q3 | 848.54 Thousand USD | 0.0% |
2009 FY | 3.39 Million USD | -12.33% |
2009 Q4 | 848.54 Thousand USD | 0.0% |
2009 Q2 | 848.54 Thousand USD | 0.0% |
2008 Q2 | 967.85 Thousand USD | 0.0% |
2008 Q4 | 967.85 Thousand USD | 0.0% |
2008 Q1 | 967.85 Thousand USD | 21.19% |
2008 Q3 | 967.85 Thousand USD | 0.0% |
2008 FY | 3.87 Million USD | 21.19% |
2007 Q3 | 798.62 Thousand USD | 0.0% |
2007 FY | 3.19 Million USD | -10.88% |
2007 Q4 | 798.62 Thousand USD | 0.0% |
2007 Q1 | 798.62 Thousand USD | -10.88% |
2007 Q2 | 798.62 Thousand USD | 0.0% |
2006 Q3 | 896.14 Thousand USD | 0.0% |
2006 Q2 | 896.14 Thousand USD | 0.0% |
2006 Q1 | 896.14 Thousand USD | 2.01% |
2006 FY | 3.58 Million USD | 2.01% |
2006 Q4 | 896.14 Thousand USD | 0.0% |
2005 FY | 3.51 Million USD | 583.98% |
2005 Q2 | 878.52 Thousand USD | 0.0% |
2005 Q3 | 878.52 Thousand USD | 0.0% |
2005 Q1 | 878.52 Thousand USD | 583.99% |
2005 Q4 | 878.52 Thousand USD | 0.0% |
2004 Q4 | 128.44 Thousand USD | 0.0% |
2004 Q2 | 128.44 Thousand USD | 0.0% |
2004 Q3 | 128.44 Thousand USD | 0.0% |
2004 Q1 | 128.44 Thousand USD | 0.0% |
2004 FY | 513.77 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Bionano Genomics, Inc. | 9.56 Million USD | -359.22% |
Prenetics Global Limited | 8.82 Million USD | -397.504% |
Star Equity Holdings, Inc. | 11.92 Million USD | -268.346% |
CareDx, Inc | 178.32 Million USD | 75.366% |
Exact Sciences Corporation | 1.84 Billion USD | 97.62% |
Exagen Inc. | 29.45 Million USD | -49.134% |
Inotiv, Inc. | 165.44 Million USD | 73.448% |
Guardant Health, Inc. | 336.89 Million USD | 86.961% |
Biodesix, Inc. | 36.07 Million USD | -21.765% |
BioNexus Gene Lab Corp. | 1.32 Million USD | -3204.179% |
Precipio, Inc. | 6.01 Million USD | -629.96% |
iSpecimen Inc. | 5.1 Million USD | -760.018% |
Natera, Inc. | 492.74 Million USD | 91.085% |
Aspira Women's Health Inc. | 5.26 Million USD | -734.835% |
Standard BioTools Inc. | 50.45 Million USD | 12.926% |
23andMe Holding Co. | 99.37 Million USD | 55.796% |
Castle Biosciences, Inc. | 174.8 Million USD | 74.87% |
Personalis, Inc. | 18.2 Million USD | -141.262% |
Aclaris Therapeutics, Inc. | 13.16 Million USD | -233.604% |
Applied DNA Sciences, Inc. | 5.53 Million USD | -693.883% |
OpGen, Inc. | -90.69 Thousand USD | 48536.501% |
T2 Biosystems, Inc. | -8.17 Million USD | 637.687% |
Myriad Genetics, Inc. | 476.4 Million USD | 90.779% |
ICON Public Limited Company | 1.81 Billion USD | 97.579% |
NeoGenomics, Inc. | 244.6 Million USD | 82.041% |
Star Equity Holdings, Inc. | 11.92 Million USD | -268.346% |
IDEXX Laboratories, Inc. | 2.18 Billion USD | 97.994% |
RadNet, Inc. | 93 Million USD | 52.765% |
Psychemedics Corporation | 8.41 Million USD | -422.156% |
Illumina, Inc. | 2.74 Billion USD | 98.399% |
Check-Cap Ltd. | -212 Thousand USD | 20821.226% |
Twist Bioscience Corporation | 133.34 Million USD | 67.057% |
DarioHealth Corp. | 5.98 Million USD | -634.108% |
Fulgent Genetics, Inc. | 104.45 Million USD | 57.945% |
Sera Prognostics, Inc. | 96 Thousand USD | -45659.375% |
ENDRA Life Sciences Inc. | -275.45 Thousand USD | 16048.027% |
OPKO Health, Inc. | 318.12 Million USD | 86.191% |
Medpace Holdings, Inc. | 524.5 Million USD | 91.625% |
Neogen Corporation | 463.9 Million USD | 90.531% |
Intelligent Bio Solutions Inc. | 1.42 Million USD | -2981.383% |
Prenetics Global Limited | 8.82 Million USD | -397.504% |
Mainz Biomed B.V. | 509.65 Thousand USD | -8519.293% |
bioAffinity Technologies, Inc. | 791.61 Thousand USD | -5449.288% |
Trinity Biotech plc | 19.45 Million USD | -125.856% |
Neuronetics, Inc. | 51.7 Million USD | 15.039% |
Sotera Health Company | 577.15 Million USD | 92.389% |
bioAffinity Technologies, Inc. | 791.61 Thousand USD | -5449.288% |